Tags : therapy

Boehringer Ingelheim Initiates P-II Study of BI 764198 for Patients

Shots: The P-II trial will assess BI 764198 (qd for ~4wks.) in patients hospitalized for COVID-19 with expected enrollment initiation in Oct’2020. The 1EPs will be the percentage of patients who are alive and free of mechanical ventilation at day 29 of treatment while other EPs include clinical improvement, oxygen saturation & ICU admission The […]Read More

Takeda Reports Results of Entyvio (vedolizumab) in Interim Analysis from

Shots: The ongoing P-IIIb VISIBLE OLE study involves assessing of Entyvio (SC) in adult patients with UC or CD, following enrolment and participation in the VISIBLE 1 (UC) or VISIBLE 2 (CD) studies. Patients who completed the maintenance period up to 52wks. (randomized completers) or who achieved clinical response @14wks. (non-randomized 14wks. responders) after a […]Read More

AbbVie and Neurocrine’s Oriahnn Receive the US FDA’s Approval as

Shots: The approval follows P-III ELARIS UF-I and ELARIS UF-II studies assessing Oriahnn (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) vs PBO for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women for up to 24mos. The study met its 1EPs of clinically meaningful reduction in bleeding (defined as the […]Read More

Boehringer Ingelheim Signs a Second Research Collaboration with Saniona to

Shots: Saniona to receive up to $84.6 as milestones along with royalties on sales of the therapies. Boehringer Ingelheim to get an exclusive global right to research, develop, manufacture and commercialize therapeutics, identified under the collaboration The focus of the collaboration is to identify new therapies for schizophrenia by utilizing Saniona’s ion channel drug discovery […]Read More

TB Alliance’s Pretomanid Combination Therapy Receives the US FDA’s Approval

Shots: The approval is based on the Nix-TB trial assessing bedaquiline, pretomanid and linezolid collectively called BPaL regimen in 109 patients with XDR-TB treatment-intolerant or non-responsive MDR-TB across three sites in South Africa The study demonstrated successful outcomes in @6mos. 95/107 patients and for two of the patients the study was extended to nine months. […]Read More